Background Multiple vaccine candidates against COVID-19 are currently being evaluated.
We evaluate the safety and immunogenicity protein of a novel SARS-CoV-2 virus receptor-…

Background SOBERANA 02 has been evaluated in phase I and IIa studies comparing
homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we …

Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …

Objectives To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o)
combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods A …

Background A phase 1, clinical trial to evaluate FINLAY-FR-1A vaccine in COVID-19
convalescent individuals was completed. Here, we report results of the phase 2, clinical trial. …

Background We report results of immunogenicity, safety and reactogenicity of SOBERANA
02 in a two-dose or three-dose heterologous scheme in adults in a phase IIb clinical trial. …

SARS-CoV-2, a recently emerged coronavirus, is causing high morbidity and mortality
worldwide since December 2019, posing an enormous health, social and economic problem. …

… Maria Eugenia Toledo-Romani; Leslihana Verdecia Sanchez; Meybis Rodriguez
Gonzalez; Laura Rodriguez Noda; Carmen Valenzuela Silva; Beatriz Paredes Moreno; …

Objectives To evaluate heterologous scheme in children 3-18 y/o using two SARS-CoV-2 r-RBD
protein vaccines. Methods A phase I/II open-label, adaptive and multicenter trial …

Background: SOBERANA 02 have been evaluated in phase I and IIa studies comparing
homologous vs. heterologous schedule (this one, including SOBERANA Plus). Here, we report …